Eli Lilly’s recent launch of its Employer Connect platform has been widely covered as another development in the GLP-1 conversation. But this isn’t simply a story about obesity medications. It reflects a shift in how access to high-cost therapies is structured, financed, and governed.
Lilly introduced Employer Connect as a direct-to-employer platform designed to help companies expand coverage of its obesity drug Zepbound through defined pricing pathways and third-party administrative partnerships. Rather than relying exclusively on traditional pharmacy benefit manager (PBM) contracting structures, the company is engaging employers more directly around how access is structured.
This isn’t primarily a pricing story. It’s a control and governance story. For employers, this introduces new pathways for access, new complexity in cost oversight, vendor alignment, and long-term financial accountability.
For HR and benefits leaders, that shift deserves attention.
Why This Is Happening Now
Several forces are converging.
GLP-1 medications have moved firmly into mainstream employer strategy, with approximately 25% of employers reporting coverage for weight loss and adoption significantly higher among larger organizations. At the same time, rising pharmacy costs tied to GLP-1 demand are increasingly viewed as a strategic risk within employer benefits planning.
Scrutiny around PBM pricing and rebate structures has also intensified, with increased focus on transparency, rebate practices, and market concentration. Employers are increasingly questioning whether traditional rebate-driven models align with long-term cost discipline.
Employers are also under growing fiduciary pressure to demonstrate structured oversight of high-cost medications. Obesity medications represent sustained multi-year cost exposure, making coverage expansion a financial governance decision, not simply a benefits enhancement.
In response, manufacturers are exploring more direct engagement models with employers, including models designed to improve access and reduce reliance on traditional PBM channels.
At the same time, pricing strategies are evolving. Novo Nordisk has announced plans to reduce list prices for its GLP-1 medications beginning in 2027, though early analysis suggests that lower list prices may not materially reduce employer net costs given how existing rebate structures operate.
This matters most for self-funded employers evaluating GLP-1 strategy as part of upcoming planning cycles.
What Employer Connect Signals
Historically, manufacturers influenced access indirectly through PBMs and health plans. Employers selected a PBM partner, and the PBM managed formularies, rebates, and utilization controls.
Now because of Employer Connect, manufacturers are positioning themselves as more active participants in employer access strategy. This doesn’t eliminate PBMs. It introduces another pathway into an already complex ecosystem.
As manufacturers move closer to employers, the balance of negotiating leverage between employers, PBMs, and drug makers may continue to change. Structural change isn’t inherently positive or negative, but it does require disciplined oversight.
What This Means for HR and C-Suite Leaders
This development isn’t simply about whether to cover GLP-1 medications. It’s about how coverage fits into long-term total cost of benefits strategy.
Three areas deserve careful evaluation:
1. Total cost impact over time
Direct manufacturer pathways often emphasize simplified or transparent pricing. That can be appealing in a rebate-driven environment. However, cost remains the dominant concern in GLP-1 coverage decisions, with employers citing affordability and sustained utilization as key barriers.
GLP-1 medications are often long-duration therapies. Expanded access may increase both utilization and persistence. Lower acquisition cost doesn’t necessarily translate into lower total plan spend. Employers should model multi-year impact scenarios before viewing direct pathways as cost solutions.
2. Governance and utilization controls
Expanded access requires guardrails.
Among employers that do offer GLP-1 coverage, most apply clinical or cost management controls, reflecting a move toward managed access rather than open-ended coverage. Many employers also implement clinical and utilization controls to manage exposure.
Any manufacturer-supported pathway should align with existing governance standards, including:
- Defined eligibility criteria
- Clinical prior authorization protocols
- Duration limits
- Reauthorization frequency
- Ongoing monitoring and reporting
Pharmacy decisions are subject to scrutiny from finance leaders and boards. Clear governance standards protect both the organization and the benefit strategy.
3. Vendor alignment and ecosystem complexity
Most employers already manage multiple benefit partners across medical, pharmacy, specialty, digital health, and stop-loss coverage.
Introducing a manufacturer-supported access channel requires clarity:
- How does this integrate with the current PBM contract?
- Does it affect rebate guarantees or contractual performance terms?
- How does it interact with stop-loss risk?
- Who owns reporting and overall cost and utilization oversight?
For example, if a manufacturer-supported pathway operates outside your primary PBM contract, rebate guarantees, reporting alignment, or stop-loss coordination could be affected. Without clarity, employers could unintentionally create parallel pharmacy channels with inconsistent oversight. In practice, this can spread pharmacy spend across multiple channels, reducing visibility and making cost forecasting more difficult without centralized oversight.
The risk isn’t expanded access itself. The risk is fragmented oversight. As manufacturers create parallel pathways into employer benefits, decision-making authority can become diffused across multiple partners. When oversight becomes diffused, cost predictability and accountability can erode. For employers already managing rising specialty spend and increased fiduciary scrutiny, that isn’t a minor operational detail. It’s a governance issue.
It’s a Governance Story
This development reflects a broader shift in governance and control. These models are neither inherently risky nor inherently cost-saving. Their impact depends on how disciplined employers are in integration, oversight, and long-term cost modeling.
The opportunity for employers isn’t speed. It’s structure.
Practical Next Steps for Employers
If you’re evaluating manufacturer-direct or manufacturer-supported programs:
- Stress test multi-year financial exposure under realistic utilization scenarios
- Ensure any new pathway adheres to the same clinical governance standards as your core pharmacy benefit
- Review PBM and stop-loss contracts before layering new access models
- Align finance, HR, and pharmacy leadership before making structural changes
Strategic alignment matters more than reacting to headlines.
The Bottom Line
Lilly’s Employer Connect platform signals a broader trend: manufacturers are positioning themselves closer to employer benefit strategy.
For HR and C-suite leaders, this isn’t merely about obesity drug access. It’s about who controls benefit design, how oversight is maintained, and whether long-term cost stability remains intact.
The employers who navigate this shift successfully won’t be those who move fastest, but those who maintain the clearest and most disciplined governance structure as the pharmacy landscape continues to evolve.
Need Help With Your GLP 1 or Pharmacy Strategy?
GLP 1 coverage decisions raise different questions for every organization. Reach out to learn how Sequoia can help you consider how these choices fit into your broader benefits approach.




